Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Coe, Jotham W., Brooks, Paige R., Vetelino, Michael G., Wirtz, Michael C., Arnold, Eric P., Huang, Jianhua, Sands, Steven B., Davis, Thomas I. +13 more·2005·Journal of Medicinal Chemistry
DOI 10.1021/jm050069n

Cited by (960)

Items 101–200 of 960

  1. Nicotine receptor partial agonists for smoking cessation
    Jonathan Livingstone‐Banks, Thomas R. Fanshawe, Kyla H Thomas, Annika Theodoulou, Anisa Hajizadeh, Lilian Hartman, Nicola Lindson · 2023 · Cochrane Database of Systematic Reviews
  2. Cys-Loop Neuroreceptors: Structure to the Rescue?
    Dennis A. Dougherty · 2008 · Chemical Reviews
  3. Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice
    Linzy M. Hendrickson, Rubing Zhao-Shea, Andrew R. Tapper · 2009 · Psychopharmacology
  4. Smoking Behaviour and Mental Health Disorders—Mutual Influences and Implications for Therapy
    Amedeo Minichino, Francesco Saverio Bersani, Wanda Katharina Calò, Francesco Spagnoli, Marta Francesconi, Roberto Vicinanza, Roberto Delle Chiaie, Massimo Biondi · 2013 · International Journal of Environmental Research and Public Health
  5. Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers
    Hélène M. Faessel, Bill J. Smith, Megan A. Gibbs, Jason S. Gobey, David J. Clark, Aaron H. Burstein · 2006 · The Journal of Clinical Pharmacology
  6. Partial Agonists of the α3β4* Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in Rats
    Susmita Chatterjee, Pia Steensland, Jeffrey A. Simms, Joan Y. Holgate, Jotham W. Coe, Raymond S Hurst, Christopher L. Shaffer, John A. Lowe III, Hans Rollema, Selena E. Bartlett · 2010 · Neuropsychopharmacology
  7. Prescription Drugs Associated with Reports of Violence Towards Others
    Thomas J. Moore, Joseph Glenmullen, Curt Daniel Furberg · 2010 · PLoS ONE
  8. Activation of α4* nAChRs is Necessary and Sufficient for Varenicline-Induced Reduction of Alcohol Consumption
    Linzy M. Hendrickson, Rubing Zhao-Shea, Xue-Yan Pang, Paul D Gardner, Andrew R. Tapper · 2010 · Journal of Neuroscience
  9. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice
    Helen M. Kamens, Jimena Andersen, Marina R. Picciotto · 2010 · Psychopharmacology
  10. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control
    Jelte A. Wouda, Danai Riga, Wendy de Vries, Mathijs Stegeman, Yvar van Mourik, Dustin Schetters, Anton N. M. Schoffelmeer, Tommy Pattij, Taco J. De Vries · 2011 · Psychopharmacology
  11. Neuronal Nicotinic Acetylcholine Receptors as Pharmacotherapeutic Targets for the Treatment of Alcohol Use Disorders
    S. Chatterjee, Selena E. Bartlett · 2010 · CNS & Neurological Disorders - Drug Targets
  12. Nicotinic pharmacophore: The pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH
    Angela P. Blum, Henry A. Lester, Dennis A. Dougherty · 2010 · Proceedings of the National Academy of Sciences
  13. Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotine acetylcholine receptors
    Grady, Sharon R., Drenan, Ryan M., Breining, Scott R., Yohannes, Daniel, Wageman, Charles R., Fedorov, Nikolai B., McKinney, Sheri, Whiteaker, Paul, Bencherif, Merouane, Lester, Henry A. et al. · 2010 · Neuropharmacology
  14. Varenicline and bupropion sustained-release combination therapy for smoking cessation
    Jon O. Ebbert, Ivana T. Croghan, Amit Sood, Darrell R. Schroeder, James Taylor Hays, R. Douglas Hurt · 2009 · Nicotine & Tobacco Research
  15. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives
    Vinay Parikh, Munir Gunes Kutlu, Thomas J. Gould · 2016 · Schizophrenia Research
  16. Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists
    Daniel P. Walker, Donn G. Wishka, David W. Piotrowski, Shaojuan Jia, Steven C. Reitz, Karen M. Yates, Jason K. Myers, Tatiana N. Vetman, Brandon J. Margolis, E. Jon Jacobsen et al. · 2006 · Bioorganic & Medicinal Chemistry
  17. Genetics of nicotine dependence and pharmacotherapy
    Christina N. Lessov‐Schlaggar, Michele L. Pergadia, Taline V. Khroyan, Gary E. Swan · 2007 · Biochemical Pharmacology
  18. Neuropharmacology and potential efficacy of new treatments for tobacco dependence
    Karl Olov Fagerström, David J.K. Balfour · 2006 · Expert Opinion on Investigational Drugs
  19. Pyridine sulfinates as general nucleophilic coupling partners in palladium-catalyzed cross-coupling reactions with aryl halides
    Tim Markovic, Benjamin N. Rocke, David C. Blakemore, Vincent Mascitti, Michael C. Willis · 2017 · Chemical Science
  20. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking
    Stephanie S. O’Malley, Allen Zweben, Lisa M. Fucito, Ran Wu, Mary E. Piepmeier, David M. Ockert, Krysten W. Bold, Ismene L. Petrakis, Srinivas B. Muvvala, Peter I. Jatlow et al. · 2017 · JAMA Psychiatry
  21. Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development
    Colleen A. Hanlon, Logan Thorne Dowdle, Joshua Henderson · 2018 · Pharmacological Reviews
  22. PPARα Regulates Cholinergic-Driven Activity of Midbrain Dopamine Neurons via a Novel Mechanism Involving α7 Nicotinic Acetylcholine Receptors
    Miriam Melis, Simona Scheggi, Gianfranca Carta, Camilla Madeddu, Salvatore Lecca, Antonio Luchicchi, Francesca Cadeddu, Roberto Frau, Liana Fattore, Paola Fadda et al. · 2013 · Journal of Neuroscience
  23. Intravenous nicotine self-administration and cue-induced reinstatement in mice: Effects of nicotine dose, rate of drug infusion and prior instrumental training
    Christie D. Fowler, Paul J. Kenny · 2011 · Neuropharmacology
  24. Medications for substance use disorders
    Douaihy, Antoine B., Kelly, Thomas M., Sullivan, Carl · 2013 · Social Work in Public Health
  25. Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers
    Hélène M. Faessel, Megan A. Gibbs, David J. Clark, Kevin D. Rohrbacher, Marilyn J. Stolar, Aaron H. Burstein · 2006 · The Journal of Clinical Pharmacology
  26. A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates
    Steven I. Rennard, J. Hughes, Paul M. Cinciripini, Eva Králíková, Tobias Raupach, Carmen Arteaga, Lisa St Aubin, Cristina Russ, for the Flexible Quit Date Study Group · 2011 · Nicotine & Tobacco Research
  27. Pharmacotherapy for Alcohol Use Disorder
    Robert M. Swift, Elizabeth R. Aston · 2015 · Harvard Review of Psychiatry
  28. Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
    Wolfgang Froestl, Andreas Muhs, Andrea Pfeifer · 2012 · Journal of Alzheimer s Disease
  29. Discovery and development of varenicline for smoking cessation
    Chloe J. Jordan, Zheng‐Xiong Xi · 2018 · Expert Opinion on Drug Discovery
  30. Review of the role of cigarette smoking in diabetic foot
    Nan Xia, Afsaneh Morteza, Fengyu Yang, Hong Cao, Aiping Wang · 2018 · Journal of Diabetes Investigation
  31. Use of Varenicline for 4 Weeks Before Quitting Smoking
    Peter Hájek, Hayden J. McRobbie, Katie Myers, John Stapleton, Al‐Rehan Dhanji · 2011 · Archives of Internal Medicine
  32. Combination Treatment With Varenicline and Bupropion in an Adaptive Smoking Cessation Paradigm
    Jed E. Rose, Frédérique M. Behm · 2014 · American Journal of Psychiatry
  33. Varenicline for smoking cessation: A placebo‐controlled, randomized study
    Chen Wang, Dan Xiao, Kenneth Chan, Chaicharn Pothirat, Dahlia Garza, Simon DAVIES · 2009 · Respirology
  34. Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease
    Jerrel L. Yakel · 2013 · Pflügers Archiv - European Journal of Physiology
  35. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect
    Rollema, Hans, Guanowsky, Victor, Mineur, Yann S., Shrikhande, Alka, Coe, Jotham W., Seymour, Patricia A., Picciotto, Marina R. · 2009 · European Journal of Pharmacology
  36. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
    K. Fagerström, Hans Gilljam, M. Metcalfe, Serena Tonstad, Michael Messig · 2010 · BMJ
  37. A Flexible Strategy for the Synthesis of Tri‐ and Tetracyclic Lupin Alkaloids: Synthesis of (+)‐Cytisine, (±)‐Anagyrine, and (±)‐Thermopsine
    Diane Gray, Timothy C. Gallagher · 2006 · Angewandte Chemie International Edition
  38. Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds
    Aleksandra Leśniewska, Piotr Przybylski · 2024 · European Journal of Medicinal Chemistry
  39. Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study
    Bo Feng, RS Obach, AH Burstein, DJ Clark, SM de Morais, H. M. Faessel · 2007 · Clinical Pharmacology & Therapeutics
  40. Efficacy and Safety of Varenicline for Smoking Cessation
    James Taylor Hays, Jon O. Ebbert, Amit Sood · 2008 · The American Journal of Medicine
  41. Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer's Disease Brain
    Ruiqing Ni, Amelia Marutle, Agneta K. Nordberg · 2013 · Journal of Alzheimer s Disease
  42. Neuroimmune nexus in the pathophysiology and therapy of inflammatory disorders: Role of α7 nicotinic acetylcholine receptors
    Keever, Kasey R., Yakubenko, Valentin P., Hoover, Donald B. · 2023 · Pharmacological Research
  43. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial
    Natalie K. Walker, Barry D. Smith, Joanne Barnes, Marjolein E. A. Verbiest, Varsha Parag, Subhash Pokhrel, Mary‐Kaye Wharakura, Tina Lees, Huber Cubillos Gutierrez, Brian Jones et al. · 2021 · Addiction
  44. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts
    Gouri Shanker, Jimmy L. Kontos, Delrae M. Eckman, Deborah J. Wesley-Farrington, David C. Sane · 2006 · Journal of Thrombosis and Thrombolysis
  45. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research
    Bruce K. Cassels, Isabel Bermúdez, Federico Dajas, Juan Andrés Abin‐Carriquiry, Susan Wonnacott · 2005 · Drug Discovery Today
  46. The Health Effect of Psychostimulants: A Literature Review
    Thierry Favrod-Coune, Barbara Broers · 2010 · Pharmaceuticals
  47. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies
    Alan S. Lewis, Gerrit Ian van Schalkwyk, Michael H. Bloch · 2017 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  48. Nicotinic acetylcholine receptors: an overview on drug discovery
    Dieter D’hoedt, Daniel Bertrand · 2009 · Expert Opinion on Therapeutic Targets
  49. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial
    Robert C. Smith, Revital Amiaz, Tianmei Si, Lawrence A. Maayan, Hua Jin, Sylvia Boules, Henry W. Sershen, Chunming Li, Juanjuan Ren, Yanhong Liu et al. · 2016 · PLoS ONE
  50. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats
    Costello, Matthew R, Reynaga, Daisy D, Mojica, Celina Y, Zaveri, Nurulain T, Belluzzi, James D, Leslie, Frances M · 2014 · Neuropsychopharmacology
  51. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats
    Mark G. LeSage, David Shelley, Jason T. Ross, Frank Ivy Carroll, William A. Corrigall · 2008 · Pharmacology Biochemistry and Behavior
  52. Nicotinic mechanisms influencing synaptic plasticity in the hippocampus
    Placzek, Andon Nicholas, Zhang, Tao A, Dani, John Anthony · 2009 · Acta Pharmacologica Sinica
  53. Cytisine and cytisine derivatives. More than smoking cessation aids
    Cecilia Gotti, Francesco Clementi · 2021 · Pharmacological Research
  54. Combination treatment with varenicline and nicotine replacement therapy
    Jon O. Ebbert, Michael V. Burke, James Taylor Hays, R. Douglas Hurt · 2009 · Nicotine & Tobacco Research
  55. Varenicline in the treatment of tobacco dependence
    Karl Olov Fagerström · 2008 · Neuropsychiatric Disease and Treatment
  56. Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the α7 nicotinic acetylcholine receptor subunit
    Salas, Ramiro, Main, Adam, Gangitano, David, De Biasi, Mariella · 2007 · Neuropharmacology
  57. Functional alterations by a subgroup of neonicotinoid pesticides in human dopaminergic neurons
    Dominik Loser, M.G. Hinojosa, Jonathan H. Blum, Jasmin Schaefer, Markus Brüll, Ylva Johansson, Ilinca Suciu, Karin Grillberger, Timm Danker, Clemens Möller et al. · 2021 · Archives of Toxicology
  58. Discovery of 4-(5-Methyloxazolo[4,5- b ]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
    Christopher J. O’Donnell, Bruce N. Rogers, Brian S. Bronk, Dianne K. Bryce, Jotham W. Coe, Karen K. Cook, Allen J. Duplantier, Edelweiss Evrard, Mihály Hajós, William E. Hoffmann et al. · 2009 · Journal of Medicinal Chemistry
  59. Varenicline and Cytisine Diminish the Dysphoric-Like State Associated with Spontaneous Nicotine Withdrawal in Rats
    Moe Igari, Jon C. Alexander, Yue Ru Ji, Xiaoli Qi, Roger L. Papke, Adriaan W. Bruijnzeel · 2013 · Neuropsychopharmacology
  60. Cholinergic Functioning in Stimulant Addiction
    Mehmet Sofuoglu, Marc E. Mooney · 2009 · CNS Drugs
  61. New horizons for therapeutics in drug and alcohol abuse
    Bianca Jupp, Andrew John Lawrence · 2009 · Pharmacology & Therapeutics
  62. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats
    Luping Z. Huang, Carla Campos, Jason Ly, Frank Ivy Carroll, Maryka Quik · 2011 · Neuropharmacology
  63. A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation
    Kate Cahill, Lindsay F Stead, Tim Lancaster · 2009 · Drug Safety
  64. 3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation
    Jotham W. Coe, Paige R. Brooks, Michael C. Wirtz, Crystal G. Bashore, Krista E. Bianco, Michael G. Vetelino, Eric P. Arnold, Lorraine A. Lebel, Carol B. Fox, Francis David Tingley et al. · 2005 · Bioorganic & Medicinal Chemistry Letters
  65. Varenicline
    Carlos Andrés Jimenez-Ruiz, Ivan Berlin, Thomas Hering · 2009 · Drugs
  66. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors
    Ronald C. Hogg, Daniel Bertrand · 2006 · Biochemical Pharmacology
  67. Biological basis of tobacco addiction: Implications for smoking-cessation treatment
    Ram Chander Jiloha · 2010 · Indian Journal of Psychiatry
  68. Nicotine receptor partial agonists for smoking cessation
    Jonathan Livingstone‐Banks, Thomas R. Fanshawe, Kyla H Thomas, Annika Theodoulou, Anisa Hajizadeh, Lilian Hartman, Nicola Lindson · 2023 · Cochrane Database of Systematic Reviews
  69. Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: Converging evidence from human and animal research
    George S. Portugal, Thomas J. Gould · 2008 · Behavioural Brain Research
  70. Varenicline Is a Potent Agonist of the Human 5-Hydroxytryptamine3 Receptor
    Sarah C. R. Lummis, Andrew J. Thompson, Merouane Bencherif, Henry A. Lester · 2011 · Journal of Pharmacology and Experimental Therapeutics
  71. Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum
    Bordia, Tanuja, Hrachova, Maya, Chin, Matthew, McIntosh, J. Michael, Quik, Maryka · 2012 · The Journal of Pharmacology and Experimental Therapeutics
  72. Vaccination against nicotine: an emerging therapy for tobacco dependence
    Patrik Maurer, Martin F. Bachmann · 2007 · Expert Opinion on Investigational Drugs
  73. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens
    Allison A. Feduccia, Jeffrey A. Simms, Douglas Mill, Henry Y. Yi, Selena E. Bartlett · 2014 · British Journal of Pharmacology
  74. Molecular actions of smoking cessation drugs at α4β2 nicotinic receptors defined in crystal structures of a homologous binding protein
    Bert Billen, Radovan Spurný, Marijke Brams, René van Elk, Soledad Valera-Kummer, Jerrel L. Yakel, Thomas Voets, Daniel Bertrand, August Benjamin Smit, Chris Ulens · 2012 · Proceedings of the National Academy of Sciences
  75. Non-Nicotinic Therapies for Smoking Cessation
    Eric C. K. Siu, Rachel Fynvola Tyndale · 2007 · The Annual Review of Pharmacology and Toxicology
  76. In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine
    Jotham W. Coe, Michael G. Vetelino, Crystal G. Bashore, Michael C. Wirtz, Paige R. Brooks, Eric P. Arnold, Lorraine A. Lebel, Carol B. Fox, Steven B. Sands, Thomas I. Davis et al. · 2005 · Bioorganic & Medicinal Chemistry Letters
  77. The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines
    David C. Swinney · 2013 · SLAS DISCOVERY
  78. Heterocycles and Medicine
    Yong‐Jin Wu · 2012 · Progress in heterocyclic chemistry
  79. The Role of the Habenula in Nicotine Addiction
    Philip Rupert Baldwin, Raul Alanis, Ramiro Salas · 2012 · Journal of Addiction Research & Therapy
  80. Nicotine Effects and the Endogenous Opioid System
    Shiroh Kishioka, Norikazu Kiguchi, Yuka Kobayashi, Fumihiro Saika · 2014 · Journal of Pharmacological Sciences
  81. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain
    Bao-Xi Gao, Markus Hierl, Kristie Clarkin, Todd Juan, Hung Quoc Nguyen, Marissa van der Valk, Hong Xin Deng, Wenhong Guo, Sonya G. Lehto, David J. Matson et al. · 2010 · Pain
  82. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
    Jon O. Ebbert · 2010 · Patient Preference and Adherence
  83. Making SharePoint® Chemically Aware™
    Kartik Tallapragada, Joseph Chewning, David C. Kombo, Beverly Ludwick · 2012 · Journal of Cheminformatics
  84. Activation and Inhibition of Mouse Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes
    Roger L. Papke, Lynn Wecker, Jerry A. Stitzel · 2010 · Journal of Pharmacology and Experimental Therapeutics
  85. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations
    Serena Tonstad, Cynthia Arons, Hans Rollema, Ivan Berlin, Peter Hájek, Karl Olov Fagerström, Charl Els, Thomas D. McRae, Cristina Russ · 2020 · Current Medical Research and Opinion
  86. Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems
    Kristen M. Mackowick, Mera S. Barr, Victoria C. Wing, Rachel Allison Rabin, Clairélaine Ouellet‐Plamondon, Tony Peter George · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  87. Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation
    Sarah E. Jackson, Jennifer McGowan, Harveen Kaur Ubhi, Hannah Proudfoot, Lion Shahab, Jamie Brown, Robert West · 2019 · Addiction
  88. Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking
    Enrique L. M. Ochoa, Jose Antonio Lasalde‐Dominicci · 2007 · Cellular and Molecular Neurobiology
  89. The Safety and Efficacy of Varenicline in Cocaine Using Smokers Maintained on Methadone: A Pilot Study
    James C. Poling, Bruce J. Rounsaville, Kishorchandra Gonsai, Kevin Severino, Mehmet Sofuoglu · 2010 · American Journal on Addictions
  90. Smoking Cessation Intervention: An Evidence-Based Approach
    Rafael Laniado-Laborı́n · 2010 · Postgraduate Medicine
  91. DARK Classics in Chemical Neuroscience: Ibogaine
    Michael J. Wasko, Paula Ann Witt‐Enderby, Christopher K. Surratt · 2018 · ACS Chemical Neuroscience
  92. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
    Raybuck, Jonathan D., Portugal, George S., Lerman, Caryn, Gould, Thomas J. · 2008 · Behavioral Neuroscience
  93. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications
    Maryka Quik, Danhui Zhang, Xiomara A. Perez, Tanuja Bordia · 2014 · Pharmacology & Therapeutics
  94. Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors
    Amol V. Shivange, Philip M. Borden, Anand K. Muthusamy, Aaron L. Nichols, Kallol Bera, Huan Bao, Isaac Bishara, Janice Jeon, Matthew J. Mulcahy, Bruce N. Cohen et al. · 2019 · The Journal of General Physiology
  95. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats
    Grażyna Biała, Natasza Staniak, Barbara Budzyńska · 2010 · Naunyn-Schmiedeberg s Archives of Pharmacology
  96. Bupropion for the treatment of nicotine withdrawal and craving
    Marc E. Mooney, Mehmet Sofuoglu · 2006 · Expert Review of Neurotherapeutics
  97. An uncontrolled trial of cytisine (Tabex) for smoking cessation: Table 1
    Witold Antoni Zatoński, Magdalena Cedzyńska, Piotr Tutka, Robert West · 2006 · Tobacco Control
  98. Addiction, cognitive decline and therapy: Seeking ways to escape a vicious cycle
    Perry, C. J., Lawrence, A. J. · 2017 · Genes, Brain and Behavior
  99. Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
    Maryka Quik, Archana Mallela, Jason Ly, Danhui Zhang · 2013 · Movement Disorders
  100. Population pharmacokinetic analysis of varenicline in adult smokers
    Patanjali Ravva, Marc R. Gastonguay, Thomas G. Tensfeldt, Hélène M. Faessel · 2009 · British Journal of Clinical Pharmacology